KR20190046365A - Method for preparing excipient for tableting comprising green tea residue and method for preparing green tea tablet using the same - Google Patents
Method for preparing excipient for tableting comprising green tea residue and method for preparing green tea tablet using the same Download PDFInfo
- Publication number
- KR20190046365A KR20190046365A KR1020170140075A KR20170140075A KR20190046365A KR 20190046365 A KR20190046365 A KR 20190046365A KR 1020170140075 A KR1020170140075 A KR 1020170140075A KR 20170140075 A KR20170140075 A KR 20170140075A KR 20190046365 A KR20190046365 A KR 20190046365A
- Authority
- KR
- South Korea
- Prior art keywords
- green tea
- residue
- extract
- tablet
- tableting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 76
- 235000009569 green tea Nutrition 0.000 title claims abstract description 71
- 239000000546 pharmaceutical excipient Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 35
- 229940094952 green tea extract Drugs 0.000 claims abstract description 43
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 43
- 238000000605 extraction Methods 0.000 claims abstract description 42
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 29
- 235000005487 catechin Nutrition 0.000 claims abstract description 29
- 239000002904 solvent Substances 0.000 claims abstract description 26
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 25
- 229950001002 cianidanol Drugs 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 21
- 239000000284 extract Substances 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 20
- 238000000227 grinding Methods 0.000 claims abstract description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 9
- 229960001948 caffeine Drugs 0.000 claims description 9
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005292 vacuum distillation Methods 0.000 claims description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 5
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 3
- 239000002699 waste material Substances 0.000 abstract description 4
- 230000000052 comparative effect Effects 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000009210 therapy by ultrasound Methods 0.000 description 5
- 235000006468 Thea sinensis Nutrition 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- YTAQZPGBTPDBPW-UHFFFAOYSA-N flavonoid group Chemical group O1C(C(C(=O)C2=CC=CC=C12)=O)C1=CC=CC=C1 YTAQZPGBTPDBPW-UHFFFAOYSA-N 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Chemical class O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000030564 negative regulation of blood pressure Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
- A23F3/32—Agglomerating, flaking or tabletting or granulating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels or liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/214—Tea
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Tea And Coffee (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 (a) 건조 녹차잎을 추출용매로 추출하여 녹차 추출물을 수득하고, 잔사(residue)를 분리하여 1차 잔사를 제조하는 단계; (b) 1차 잔사를 추출용매로 재추출하여 재추출물과 2차 잔사를 제조하는 단계; 및 (c) 재추출물과 2차 잔사를 분말화하여 타정용 부형제 분말을 제조하는 단계;를 포함하는 녹차 잔사를 포함하는 타정용 부형제의 제조방법에 관한 것이다. 이에 의하여, 타블렛 제조시 폐기물의 발생을 원천적으로 막아 폐기물 처리에 따른 공정과 비용이 발생하지 않도록 하고, 잔사에 포함된 카테킨이 녹차 타블렛에 포함되므로 카테킨의 함량을 높일 수 있다.(A) extracting a green tea leaf with an extraction solvent to obtain a green tea extract, and separating the residue to prepare a first residue; (b) re-extracting the primary residue with an extraction solvent to produce a re-extract and a secondary residue; And (c) powdering the re-extract and the secondary residue to prepare a tableting excipient powder. The present invention also relates to a method for preparing a tableting excipient comprising a green tea residue. Thus, it is possible to prevent the generation of waste during the production of the tablets, thereby avoiding the process and cost associated with the disposal of the waste, and the catechin contained in the residue is contained in the green tea tablet, thereby increasing the catechin content.
Description
본 발명은 녹차 잔사를 포함하는 타정용 부형제의 제조방법 및 그를 이용한 녹차 타블렛의 제조방법에 관한 것으로, 더욱 상세하게는 녹차 추출 후 발생하는 잔사를 폐기하지 않고 부형제로 활용할 수 있는 녹차 잔사를 포함하는 타정용 부형제의 제조방법 및 그를 이용한 녹차 타블렛의 제조방법에 관한 것이다.The present invention relates to a method for producing a tableting excipient containing green tea residue and a method for preparing a green tea tablet using the same, and more particularly, to a method for preparing a green tea tablet comprising a green tea residue which can be used as an excipient And a method for producing a green tea tablet using the same.
녹차에는 카테킨, 카페인, 아미노산, 섬유소, 펙틴, 비타민, 무기염류 등이 함유되어 이들 성분들에 의해 항산화, 항돌연변이 및 항종양작용, 콜레스테롤 상승억제에 효능을 나타내는 다양한 생리활성 물질이 포함되어 있다.Green tea contains catechins, caffeine, amino acids, fibrin, pectin, vitamins, and inorganic salts. These ingredients contain various physiologically active substances that have antioxidant, antimutagenic and antitumor actions and inhibitory effects on cholesterol elevation.
카테킨은 플라보노이드 그룹의 플라반-3-올스(flavan-3-ols)에 속하며, 폴리페놀 일종으로 녹차의 떫은 맛 성분이다. 차류(Camellia sinensis)에서 파생되었으며, 백차, 녹차, 홍차, 우롱차에 포함되어 있다. 그러나 홍차나 우롱차의 경우 발효과정에서 반 이상의 카테킨이 줄어든다. 찻잎 중의 폴리페놀은 온화한 쓴맛을 내는 유리형 카테킨과 쓰고 떫은맛을 내는 에스터형 카테킨, 강한 쓴맛과 약한 떫은맛을 내는 결합형 카테킨이 있어 감의 타닌과는 달리 단백질과 분리되어 입안이 텁텁하지 않다. 주요한 카테킨으로는 에피갈로카테킨갈레이트(EGCG: epigallocatechingallate), 에피갈로카테킨(EGC: epigallocatechin), 에피카테킨갈레이트(ECG: epicatechingallate), 에피카테킨(EC: epicatechin)이 있다.Catechin belongs to flavon-3-ols (flavan-3-ols) of the flavonoid group and is a flavor component of green tea as a polyphenol. Derived from tea (Camellia sinensis), contained in white tea, green tea, black tea and oolong tea. However, in the case of tea or oolong tea, catechin is reduced by more than half in the fermentation process. The polyphenols in tea leaves have a mild bitter taste, a catechin with a bitter flavor, an ester catechin with a bitter taste, and a catechin with a strong bitter taste and a weak bitter taste, unlike the tannins of persimmon. The main catechins are epigallocatechualate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and epicatechin (EC).
카테킨은 발암억제, 동맥경화, 혈압상승 억제, 혈전예방, 항바이러스, 항비만, 항당뇨, 항균, 해독작용, 소염작용, 충치예방, 구갈방지, 장내 세균총 정상화 등 다양한 효과가 있다. 카테킨의 항산화 작용과 노화의 근본적 요소인 자유라디컬 제거기능은 비타민C와 비타민E에 비해 강력한 활성산소 제거효과를 가지고 있으며, 항산화작용으로 인하여 저밀도 지단백(low density lipoprotein) 산화와 같은 심혈관계 보호 효과가 보고되었다. 카테킨은 바람직하지 않은 세포군집의 생산과 개시를 멈추거나 느리게 하며, DNA 손상을 경험적으로 야기하는 것들을 저지하는 것으로 나타났다.Catechin has various effects such as inhibition of carcinogenesis, arteriosclerosis, inhibition of blood pressure increase, prevention of thrombosis, antiviral, anti-obesity, antidiabetic, antibacterial, detoxifying action, anti-inflammatory action, prevention of tooth decay, prevention of browning, normalization of intestinal flora. Catechin's antioxidant and antioxidant activity, which is a fundamental element of aging, has a stronger effect on the removal of free radicals than vitamin C and vitamin E, and its antioxidant activity has the effect of protecting against cardiovascular diseases such as low density lipoprotein oxidation Was reported. Catechins have been shown to stop or slow the production and initiation of undesirable cell populations, and to inhibit those that empirically cause DNA damage.
이와 같은 카테킨의 용이한 섭취를 위하여 녹차 추출물을 타정하여 타블렛으로 제조하는 방법이 있다. 그러나 타정 과정에서 녹차 추출 후의 잔사는 전량 폐기되어 폐기물 처리 과정이 추가로 필요하고, 덱스트린, 유당 등의 부형제를 추가로 사용하여 공정 비용이 추가로 소요될 뿐 아니라, 잔사에 포함되어 있는 카테킨 성분을 활용할 수 없는 문제점이 있었다.For easy ingestion of such catechins, there is a method of tabletting green tea extract to prepare tablets. However, the residues after green tea extraction in the tableting process are all discarded and waste disposal is further required. In addition, excipients such as dextrin and lactose are additionally used to further increase the processing cost and utilize the catechin components contained in the residue There was no problem.
본 발명의 목적은 상기 문제점을 해결하기 위한 것으로, 녹차 추출물을 제조하고 남은 잔사를 이용하여 타정용 부형제를 제조하고, 이를 이용하여 녹차 타블렛 타정에 사용함으로써 폐기물의 발생을 원천적으로 막아 폐기물 처리에 따른 공정과 비용이 발생하지 않도록 하고, 잔사에 포함된 카테킨이 녹차 타블렛에 포함되므로 카테킨의 함량을 높이는 타정용 부형제의 제조방법 및 그를 포함하는 녹차 타블렛의 제조방법을 제공하는 데 있다.The object of the present invention is to solve the above-mentioned problems, and it is an object of the present invention to provide a green tea extract which is prepared by using the remaining residues to prepare tableting excipients and using the same for tableting green tea tablets, The present invention also provides a method for manufacturing a tableting excipient for increasing the content of catechin because the catechin contained in the residue is contained in the green tea tablet, and a method for producing the green tea tablet containing the same.
본 발명의 일 측면에 따르면,According to an aspect of the present invention,
(a) 건조 녹차잎을 추출용매로 추출하여 녹차 추출물을 수득하고, 잔사(residue)를 분리하여 1차 잔사를 제조하는 단계; (b) 상기 1차 잔사를 추출용매로 재추출하여 재추출물과 2차 잔사를 제조하는 단계; 및 (c) 상기 재추출물과 2차 잔사를 분말화하여 타정용 부형제 분말을 제조하는 단계;를 포함하는 녹차 잔사를 포함하는 타정용 부형제의 제조방법이 제공된다.(a) extracting a dried green tea leaf with an extraction solvent to obtain a green tea extract, and separating the residue to prepare a first residue; (b) re-extracting the primary residue with an extraction solvent to produce a re-extract and a secondary residue; And (c) powdering the re-extract and the secondary residue to prepare a tableting excipient powder. The method for manufacturing a tableting excipient including a green tea residue is provided.
단계 (a)의 상기 추출용매는 물, 탄소수 1-4의 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트, 1,3-부틸렌글리콜, 헥산, 및 디에틸에테르 중에서 선택된 1종 이상일 수 있다.The extraction solvent in step (a) may be at least one selected from water, lower alcohols having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol, hexane, and diethyl ether .
상기 추출용매는 30 내지 75% 농도의 에탄올 수용액 일 수 있다.The extraction solvent may be an ethanol aqueous solution having a concentration of 30 to 75%.
단계 (b)의 상기 재추출에 사용되는 추출용매는 물, 탄소수 1-4의 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트, 1,3-부틸렌글리콜, 헥산, 및 디에틸에테르 중에서 선택된 1종 이상일 수 있다.The extraction solvent used in the re-extraction of step (b) is selected from water, lower alcohols having 1-4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol, hexane, It may be more than one kind.
상기 재추출에 사용되는 추출용매는 60 내지 100℃의 열수일 수 있다.The extraction solvent used for the re-extraction may be hot water at 60-100 ° C.
단계 (b)의 재추출은 환류 추출에 의해 수행할 수 있다.The re-extraction of step (b) can be carried out by reflux extraction.
단계 (b)의 재추출에 의해 상기 1차 잔사에 포함된 당이 추출될 수 있다.The sugar contained in the primary residue can be extracted by re-extraction of step (b).
단계 (c)의 상기 분말화는 분무 건조, 감압 증류 및 동결 건조 중에서 선택된 어느 하나의 방법에 따라 수행될 수 있다.The pulverization of step (c) may be carried out according to any one of the methods selected from spray drying, vacuum distillation and freeze drying.
본 발명의 다른 하나의 측면에 따르면,According to another aspect of the present invention,
상기 방법에 따라 제조된 녹차 잔사를 포함하는 타정용 부형제가 제공된다.There is provided a tableting excipient comprising green tea residue prepared according to the above method.
본 발명의 다른 또 하나의 측면에 따르면,According to another aspect of the present invention,
(1) 건조 녹차잎을 추출용매로 추출하여 녹차 추출물을 수득하고, 잔사(residue)를 분리하여 1차 잔사를 제조하는 단계; (2) 상기 녹차 추출물에서 카페인 성분을 제거하여 디카페인 녹차 추출물을 제조하는 단계; (3) 상기 디카페인 녹차 추출물을 농축시켜 녹차 농축추출물을 제조하는 단계; (4) 상기 녹차 농축추출물을 분말화하여 녹차 추출분말을 제조하는 단계; 및 (5) 제1항 내지 제7항 중에서 선택된 어느 한 항에 따라 제조된 녹차 잔사를 포함하는 타정용 부형제와 상기 녹차 추출분말을 재료로 타정하여 녹차 타블렛을 제조하는 단계;를 포함하는 녹차 타블렛의 제조방법이 제공된다.(1) extracting a dried green tea leaf with an extraction solvent to obtain a green tea extract, and separating the residue to prepare a primary residue; (2) removing the caffeine component from the green tea extract to prepare a decaffeinated green tea extract; (3) concentrating the decaffeinated green tea extract to prepare a green tea concentrated extract; (4) preparing green tea extract powder by pulverizing the green tea concentrated extract; And (5) preparing a green tea tablet by tableting the tableting excipient comprising the green tea residue prepared according to any one of claims 1 to 7 and the green tea extract powder with a material, Is provided.
단계 (1)의 상기 건조 녹차잎의 카테킨 함량은 8 내지 13wt% 일 수 있다.The catechin content of the dried green tea leaves of step (1) may be 8 to 13 wt%.
단계 (2)에서 상기 녹차 추출물이 추출용매에 혼합된 상태에서 이온교환수지 처리 또는 초음파 처리함에 따라 카페인이 제거될 수 있다.In step (2), when the green tea extract is mixed with the extraction solvent, caffeine may be removed by ion-exchange resin treatment or ultrasonic treatment.
상기 초음파 처리는 10 내지 20분간 수행될 수 있다.The ultrasonic treatment may be performed for 10 to 20 minutes.
단계 (2)에서 상기 녹차 추출물이 추출용매에 혼합된 상태에서 에틸아세테이트 또는 염화메틸렌을 가하여 카페인이 제거될 수 있다.In step (2), caffeine may be removed by adding ethyl acetate or methylene chloride while the green tea extract is mixed with the extraction solvent.
단계 (3)의 농축은 감압농축 또는 원심농축에 따라 수행될 수 있다.Concentration of step (3) can be carried out according to reduced pressure or centrifugal concentration.
단계 (4)의 상기 녹차 추출분말은 평균입도가 20 내지 23㎛ 일 수 있다.The green tea extract powder of step (4) may have an average particle size of 20 to 23 탆.
단계 (4)의 상기 분말화는 분무 건조, 감압 증류 및 동결 건조 중에서 선택된 어느 하나의 방법에 따라 수행될 수 있다.The pulverization of step (4) can be carried out according to any one of the methods selected from spray drying, vacuum distillation and freeze drying.
단계 (5)에서 타정용 부형제와 상기 녹차 추출분말 3:7 내지 7:3의 중량비로 혼합하여 타정할 수 있다.In step (5), the tableting excipient and the green tea extract powder may be mixed and kneaded at a weight ratio of 3: 7 to 7: 3.
단계 (5)에서 활택제를 추가로 포함시켜 타정할 수 있다.In step (5), a lubricant may be further included to be tableted.
단계 (5)의 상기 녹차 타블렛의 카테킨 함량은 30 내지 35wt% 일 수 있다.The catechin content of the green tea tablet of step (5) may be 30 to 35 wt%.
본 발명의 다른 또 하나의 측면에 따르면,According to another aspect of the present invention,
상기 방법에 따라 제조된 녹차 타블렛이 제공된다.A green tea tablet prepared according to the above method is provided.
본 발명의 녹차 잔사를 포함하는 타정용 부형제의 제조방법 및 그를 이용한 녹차 타블렛의 제조방법은 녹차 추출물을 제조하고 남은 잔사를 이용하여 타정용 부형제를 제조하고, 이를 이용하여 녹차 타블렛 타정에 사용함으로써 폐기물의 발생을 원천적으로 막아 폐기물 처리에 따른 공정과 비용이 발생하지 않도록 하고, 잔사에 포함된 카테킨이 녹차 타블렛에 포함되므로 카테킨의 함량을 높일 수 있는 효과가 있다.The method for manufacturing a tableting excipient containing the green tea residue of the present invention and the method for manufacturing a green tea tablet using the green tea extract according to the present invention can be used for preparing a tableting excipient using a remaining green tea extract, It is possible to prevent the generation of the process and cost due to waste treatment, and the catechin contained in the residue is contained in the green tea tablet, so that the catechin content can be increased.
도 1은 본 발명의 녹차 타블렛의 제조방법과 타정용 부형제의 제조방법을 나타낸 흐름도이다.1 is a flowchart illustrating a method for manufacturing a green tea tablet and a method for manufacturing a tableting excipient according to the present invention.
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.
BRIEF DESCRIPTION OF THE DRAWINGS The present invention is capable of various modifications and various embodiments, and specific embodiments are illustrated in the drawings and described in detail in the detailed description. It is to be understood, however, that the invention is not to be limited to the specific embodiments, but includes all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail with reference to the accompanying drawings.
도 1은 본 발명의 녹차 잔사를 포함하는 타정용 부형제의 제조방법과 그 방법을 이용한 녹차 타블렛의 제조공정을 순차적으로 나타낸 흐름도이다. 이하, 도 1을 참조하여 본 발명의 녹차 잔사를 포함하는 타정용 부형제의 제조방법에 대해 설명하도록 한다.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a flowchart illustrating a method for manufacturing a tableting excipient including green tea residue according to the present invention and a process for producing a green tea tablet using the method. Hereinafter, a method for producing a tableting excipient containing green tea residue according to the present invention will be described with reference to FIG.
먼저, 건조 First, 녹차잎을Green tea leaves 추출용매로 추출하여 녹차 추출물을 수득하고, 잔사( Extracted with an extraction solvent to obtain a green tea extract, and the residue ( residueresidue )를 분리하여 1차 ) Were separated to obtain primary 잔사를The residue 제조한다(단계 a). (Step a).
상기 추출용매는 물, 탄소수 1-4의 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트, 1,3-부틸렌글리콜, 헥산, 디에틸에테르 등을 사용할 수 있다.The extraction solvent may be water, lower alcohols having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol, hexane or diethyl ether.
바람직하게는, 상기 추출용매는 30 내지 75% 농도의 에탄올 수용액일 수 있고, 더욱 바람직하게는 50 내지 75% 농도, 더욱 더 바람직하게는 60 내지 75% 농도의 에탄올 수용일 수 있다.Preferably, the extraction solvent may be an ethanol aqueous solution having a concentration of 30 to 75%, more preferably a concentration of 50 to 75%, and still more preferably a concentration of 60 to 75%.
본 명세서에서 사용되는 용어 ‘추출물’은 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함할 수 있다.As used herein, the term 'extract' has the meaning of being used as a crude extract in the art, but broadly it can also include fractions in which the extract is further fractionated.
다음으로, 상기 1차 Next, 잔사를The residue 추출용매로 재추출하여 Re-extracted with an extraction solvent 재추출물과Re-extract and 2차 Secondary 잔사를The residue 제조한다(단계 b). (Step b).
상기 재추출에 사용되는 추출용매는 물, 탄소수 1-4의 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트, 1,3-부틸렌글리콜, 헥산, 디에틸에테르 등을 사용할 수 있다.Water, a lower alcohol having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol, hexane, diethyl ether and the like can be used as the extraction solvent used for re-extraction.
바람직하게는 상기 재추출에 사용되는 추출용매는 60 내지 100℃의 열수일 수 있고, 더욱 바람직하게는 70 내지 95℃의 열수, 더욱 더 바람직하게는 80 내지 90℃의 열수를 사용할 수 있다.Preferably, the extraction solvent used for re-extraction may be hot water at 60-100 ° C, more preferably 70-95 ° C, even more preferably 80-90 ° C.
상기 재추출은 환류 추출에 의해 수행하는 것이 바람직하다.The re-extraction is preferably carried out by reflux extraction.
상기 재추출에 의해 상기 1차 잔사에 포함된 당이 추출되어 결합제 기능이 더욱 향상될 수 있다. 경우에 따라, 본 단계를 생략하고, 1차 잔사를 바로 분말화하여 부형제를 제조할 수 있으나, 이 경우 결합제 성분이 부족하여 타정이 제대로 이루어지지 않을 수 있다.The sugar contained in the primary residue may be extracted by the re-extraction to further improve the function of the binder. In some cases, this step may be omitted and the primary residue may be directly pulverized to produce an excipient. In this case, however, the binder component may be insufficient to achieve proper tableting.
마지막으로, 상기 Finally, 재추출물과Re-extract and 2차 Secondary 잔사를The residue 분말화하여Powdered 타정용Other 부형제 분말을 제조한다(단계 c). The excipient powder is prepared (step c).
상기 분말화는 분무 건조, 감압 증류, 동결 건조 등에 따라 수행할 수 있고, 바람직하게는 분무 건조에 따라 수행할 수 있다.
The pulverization may be carried out by spray drying, vacuum distillation, freeze-drying, etc., preferably spray drying.
본 발명은 상술한 녹차 잔사가 포함된 타정용 부형제의 제조방법에 따라 제조된 타정용 부형제를 제공한다.
The present invention provides a tableting excipient manufactured according to the above-described method for producing a tableting excipient containing a green tea residue.
이하, 도 1을 참조하여 본 발명의 녹차 타블렛의 제조방법에 대해 설명하도록 한다.Hereinafter, a method for manufacturing a green tea tablet of the present invention will be described with reference to FIG.
먼저, 건조 First, 녹차잎을Green tea leaves 추출용매로 추출하여 녹차 추출물을 수득하고, 잔사( Extracted with an extraction solvent to obtain a green tea extract, and the residue ( residueresidue )를 분리하여 1차 ) Were separated to obtain primary 잔사를The residue 제조한다(단계 1). (Step 1).
단계 1은 상술한 타정용 부형제이 제조방법에서의 단계 a와 동일한 방법으로 수행하는 것이므로 구체적인 내용은 그 부분을 참조하기로 한다.Step 1 is carried out in the same manner as step a in the above-mentioned method for manufacturing a tableting vehicle, and therefore, the details will be referred to.
상기 녹차 추출물의 카테킨 함량은 8 내지 13wt% 일 수 있다.The catechin content of the green tea extract may be 8 to 13 wt%.
다음으로, 상기 녹차 추출물에서 카페인 성분을 제거하여 Next, the caffeine component was removed from the green tea extract 디카페인Decaffein 녹차 추출물을 제조한다(단계 2). Green tea extract is prepared (Step 2).
녹차 추출물이 추출용매에 혼합된 상태에서 이온교환수지 처리하거나, 또는 초음파 처리함에 따라 카페인이 제거될 수 있으며, 이때 상기 초음파 처리는 10 내지 20분간 수행되는 것이 바람직하다.The caffeine may be removed by treating the green tea extract with an ion exchange resin or an ultrasonic treatment in a state where the green tea extract is mixed with the extraction solvent, and the ultrasound treatment is preferably performed for 10 to 20 minutes.
또는, 상기 녹차 추출물이 추출용매에 혼합된 상태에서 에틸아세테이트 또는 염화메틸렌을 가하여 카페인이 제거되도록 할 수도 있으나, 본 발명의 범위가 여기에 한정되지 않으며 다른 공지된 디카페인 방법을 사용할 수 있다.Alternatively, the green tea extract may be mixed with an extraction solvent to remove caffeine by adding ethyl acetate or methylene chloride. However, the scope of the present invention is not limited thereto, and other known decaffeine methods may be used.
이후, 상기 Then, 디카페인Decaffein 녹차 추출물을 농축시켜 녹차 농축추출물을 제조한다(단계 3). Green tea extract is concentrated to prepare green tea concentrated extract (step 3).
농축은 감압농축 또는 원심농축에 따라 수행될 수 있다.Concentration can be performed according to reduced pressure concentration or centrifugal concentration.
다음으로, 상기 녹차 농축추출물을 Next, the green tea concentrated extract 분말화하여Powdered 녹차 추출분말을 제조한다(단계 4). Green tea extract powder is prepared (step 4).
상기 녹차 추출분말은 평균입도가 20 내지 23㎛ 일 수 있다.The green tea extract powder may have an average particle size of 20 to 23 탆.
상기 분말화는 분무 건조, 감압 증류, 동결 건조 등에 따라 수행할 수 있고, 바람직하게는 분무 건조에 따라 수행할 수 있다.The pulverization may be carried out by spray drying, vacuum distillation, freeze-drying, etc., preferably spray drying.
마지막으로, 상술한 본 발명의 녹차 Finally, the above-described green tea of the present invention 잔사를The residue 포함하는 Included 타정용Other 부형제와 상기 녹차 추출분말을 재료로 The excipient and the green tea extract powder 타정하여By typing 녹차 green tea 타블렛을Tablet 제조한다(단계 5). (Step 5).
상기 녹차 타블렛의 카테킨 함량은 30 내지 35wt% 일 수 있다. 이와 같은 이유는 녹차 추출물에 포함된 카테킨에 부형제에 포함된 카테킨이 추가로 포함되어 카테킨의 함량이 크게 높아졌기 때문이다.
The catechin content of the green tea tablet may be 30 to 35 wt%. This is because catechin contained in green tea extract contains catechin contained in excipient and catechin content is greatly increased.
또한, 본 발명은 상술한 녹차 타블렛의 제조방법에 따라 제조된 녹차 타블렛을 제공한다.
The present invention also provides a green tea tablet produced according to the above-described method for manufacturing a green tea tablet.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시하나, 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범주 및 기술사상 범위 내에서 다양한 변경 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속하는 것도 당연한 것이다.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.
실시예Example 1 One
(1) 녹차 추출 및 잔사 수득(1) Extraction of green tea and obtaining residue
녹차잎 (제주특별자치도, 오설록농장)은 실온에서 음건하여 사용하였다. 이와 같이 준비된 녹차잎 680kg을 준비하여 70% 농도의 에탄올 수용액 10,200L를 넣고 가온하여 70℃ 도달 후 1시간 동안 추출하고 여과시켜 녹차 추출액과 잔사를 분리하였다.Green tea leaves (Jeju Special Self-Governing Province, Oedulok Farm) were used at room temperature on shade. 680 kg of the prepared green tea leaves were prepared and 10,200 L of 70% ethanol aqueous solution was added and heated. After reaching 70 캜, the mixture was extracted for 1 hour and filtered to separate the green tea extract and the residue.
(2) 녹차 추출물 제조(2) Production of green tea extract
상기 녹차 추출액에 디카페인 처리한 후 감압농축기에 의하여 용매를 제거시킨 농축추출물을 수득한 후, 분무 건조시켜 분말화하였다.The green tea extract was decaffeinated, and the concentrated extract obtained by removing the solvent by a vacuum concentrator was obtained, followed by spray drying and pulverization.
(3) 잔사 재추출 및 부형제 분말 제조(3) Extraction of residues and preparation of excipient powder
상기 잔사에 열수 3400kg을 가하여 86℃에서 환류 추출하여 잔사의 당을 추출하여 재추출물과 잔사 혼합물을 수득하고, 재추출물과 잔사 혼합물은 분무 건조시켜 분말화함으로써 부형제 분말을 제조하였다. 3400 kg of hot water was added to the residue, and the mixture was refluxed at 86 ° C to extract the residue sugar to obtain a re-extract and a residue mixture. The re-extract and the residue mixture were spray-dried and powdered to prepare an excipient powder.
(4) 녹차 타블렛 제조(4) Manufacture of green tea tablets
공정 (2)에서 얻은 녹차 추출분말, 공정 (3)에서 얻은 부형제 분말, 활택제인 무수규산, 스테아린산 마그네슘을 55:44:0.5:0.5의 중량비로 혼합하고, 직경 15mm 두께 7mm의 크기로 타정압 500kgf으로 타정하여 녹차 타블렛을 제조하였다. 제조된 녹차 총 중량은 198.6kg으로 수율은 29.2% 였다.
The green tea extract powder obtained in the step (2), the excipient powder obtained in the step (3), anhydrous silicic acid and magnesium stearate were mixed at a weight ratio of 55: 44: 0.5: 0.5, To prepare a green tea tablet. The total weight of the prepared green tea was 198.6 kg and the yield was 29.2%.
비교예Comparative Example 1 One
잔사 재추출 공정을 생략하고 잔사를 그대로 분말화 한 것을 부형제로 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 녹차 타블렛을 제조하였다. 제조된 녹차 타블렛의 총 중량은 202.4kg으로 수율은 29.8% 였다.
A green tea tablet was prepared in the same manner as in Example 1, except that the residue re-extraction step was omitted and the residue was directly pulverized as an excipient. The total weight of the prepared green tea tablet was 202.4 kg, and the yield was 29.8%.
비교예Comparative Example 2 2
공정 (3)에서 얻은 부형제 분말 대신에 덱스트린을 부형제로 사용한 것을 제외하고는 실시예 1과 동일한 방법으로 녹차 타블렛을 제조하였다. 제조된 녹차 타블렛의 총중량은 180kg으로 수율은 26.5% 였다. 또한, 녹차 추출 후 발생한 약 500kg의 잔사는 폐기 처리되었으며, 폐기비용은 통상적으로 톤당 75,000원이 소요되었다.
A green tea tablet was prepared in the same manner as in Example 1 except that dextrin was used as an excipient instead of the excipient powder obtained in the step (3). The total weight of the prepared green tea tablet was 180 kg, and the yield was 26.5%. In addition, about 500 kg of residue generated after green tea extraction was disposed of, and the disposal cost was normally 75,000 won per ton.
[시험예][Test Example]
시험예Test Example 1: 카테킨 함량 분석 1: Analysis of catechin content
실시예 1, 비교예 1 및 비교예 2에 따라 제조된 타블렛을 각각 분쇄한 시료 0.5g에 50% 메탄올수용액을 100㎖ 첨가하고 20~30분간 초음파처리하여 추출한 시료를 0.45㎛ 멤브레인 필터로 여과하여 HPLC(고속액체 크로마토그래피)로 분석하였으며, 시료의 주입량은 각각 10㎕가 되도록 하고 gradient 방법을 사용하였다.100 ml of a 50% methanol aqueous solution was added to 0.5 g of each sample obtained by crushing the tablets prepared in Example 1, Comparative Example 1 and Comparative Example 2, and the resulting sample was subjected to ultrasonic treatment for 20 to 30 minutes, filtered through a 0.45 탆 membrane filter HPLC (High Performance Liquid Chromatography), and the amount of injected sample was 10 μl each, and gradient method was used.
분석 결과, 카테킨 함량은 실시예 1의 시료가 24.3%, 비교예 1은 24.1%, 비교예 2는 19.6%로 나타나 잔사를 부형제로 사용한 녹차 타블렛이 상대적으로 높은 카테킨 함량을 나타내었다.
As a result, the catechin content of the sample of Example 1 was 24.3%, that of Comparative Example 1 was 24.1%, and that of Comparative Example 2 was 19.6%. Thus, the green tea tablet using the residue as an excipient showed a relatively high catechin content.
시험예Test Example 2: 2: 타블렛의Tablet 물성 평가 Property evaluation
실시예 1, 비교예 1 및 비교예 2에 따라 제조된 타블렛에 대해 경도, 붕해시간, 마손도를 평가하였다. 경도는 미국 약전(USP) 1217장(tablet breaking force)에 따라 측정하였으며 붕해시간은 미국약전(USP) 701장(Disinteration)에 따라 측정하였으며 마손도는 미국 약전(USP)의 1216장(tablet friability)에 따라 마손 시험을 수행한 후 하기 식에 따라 마손도를 측정하여 그 결과를 아래의 표 1에 정리하였다.The tablets prepared according to Example 1, Comparative Example 1 and Comparative Example 2 were evaluated for hardness, disintegration time, and degree of abrasion. Hardness was measured according to United States Pharmacopoeia (USP) 1217 (tablet breaking force) and the disintegration time was measured according to USP 701 (Disinteration), and the degree of malondialdehyde was determined according to USP 1216 (tablet friability) , And the results are shown in Table 1 below. ≪ tb > < TABLE >
[식][expression]
마손도(%)=(초기정제 20정의 무게(mg) - 마손시험 후 정제 20정의 무게(mg))/초기정제 20정의 무게 ⅹ 100(%) (%) = (Initial tablet 20 defined weight (mg) - refined tablet 20 after weight loss test (mg)) / initial tablet 20 defined weight x 100 (%)
표 1에 따르면, 실시예 1의 타블렛은 녹차 잔사를 부형제로 사용하면서도 종래 덱스트린을 부형제로 사용한 비교예 2의 타블렛과 경도, 마손도 및 붕해 시간 평가에서 큰 차이를 나타내지 않았다. 그러나, 재추출을 하지 않은 잔사를 그대로 부형제로 사용한 비교예 1의 타블렛은 경도가 상대적으로 낮고 마손도가 높은 것으로 나타났다. 이와 같은 결과는 잔사의 재추출 과정에서 잔사에 포함된 당이 추출되고, 추출된 당이 포함된 재추출물이 부형제에 포함되면서 결합제 역할을 하여 실시예 1의 타블렛의 경도가 높아진 것으로 판단된다.
According to Table 1, the tablet of Example 1 showed no significant difference in evaluation of hardness, degree of shrinkage and disintegration time with the tablet of Comparative Example 2, which used conventional dextrin as an excipient while using green tea residue as an excipient. However, the tablet of Comparative Example 1 using the residue as the excipient without re-extraction showed a relatively low hardness and a high degree of scratching. These results indicate that the sugar contained in the residue is extracted during the re-extraction of the residue, and the re-extract containing the extracted sugar is included in the excipient, thereby acting as a binder, and thus the hardness of the tablet of Example 1 is increased.
이상, 본 발명의 실시예들에 대하여 설명하였으나, 해당 기술 분야에서 통상의 지식을 가진 자라면 특허청구범위에 기재된 본 발명의 사상으로부터 벗어나지 않는 범위 내에서, 구성 요소의 부가, 변경, 삭제 또는 추가 등에 의해 본 발명을 다양하게 수정 및 변경시킬 수 있을 것이며, 이 또한 본 발명의 권리범위 내에 포함된다고 할 것이다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, many modifications and changes may be made by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims. The present invention can be variously modified and changed by those skilled in the art, and it is also within the scope of the present invention.
Claims (11)
(b) 상기 1차 잔사를 추출용매로 재추출하여 재추출물과 2차 잔사를 제조하는 단계; 및
(c) 상기 재추출물과 2차 잔사를 분말화하여 타정용 부형제 분말을 제조하는 단계;를 포함하는 녹차 잔사를 포함하는 타정용 부형제의 제조방법.(a) extracting a dried green tea leaf with an extraction solvent to obtain a green tea extract, and separating the residue to prepare a first residue;
(b) re-extracting the primary residue with an extraction solvent to produce a re-extract and a secondary residue; And
(c) powdering the re-extract and the second residue to prepare a tableting excipient powder. The method of manufacturing a tableting excipient comprising green tea residue.
단계 (a) 또는 (b)의 상기 추출용매는 물, 탄소수 1-4의 저급 알코올, 아세톤, 에틸 아세테이트, 클로로포름, 부틸아세테이트, 1,3-부틸렌글리콜, 헥산, 및 디에틸에테르 중에서 선택된 1종 이상인 것을 특징으로 하는 녹차 잔사를 포함하는 타정용 부형제의 제조방법.The method according to claim 1,
The extraction solvent of step (a) or (b) is selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, acetone, ethyl acetate, chloroform, butyl acetate, 1,3-butylene glycol, hexane, Of the total amount of the green tea residue.
단계 (c)의 상기 분말화는 분무 건조, 감압 증류 및 동결 건조 중에서 선택된 어느 하나의 방법에 따라 수행되는 것을 특징으로 하는 타정용 부형제의 제조방법.The method according to claim 1,
Wherein the pulverization of step (c) is carried out according to any one of spray drying, vacuum distillation and freeze drying.
(2) 상기 녹차 추출물에서 카페인 성분을 제거하여 디카페인 녹차 추출물을 제조하는 단계;
(3) 상기 디카페인 녹차 추출물을 농축시켜 녹차 농축추출물을 제조하는 단계;
(4) 상기 녹차 농축추출물을 분말화하여 녹차 추출분말을 제조하는 단계; 및
(5) 제1항 내지 제3항 중에서 선택된 어느 한 항에 따라 제조된 녹차 잔사를 포함하는 타정용 부형제와 상기 녹차 추출분말을 재료로 타정하여 녹차 타블렛을 제조하는 단계;를 포함하는 녹차 타블렛의 제조방법.(1) extracting a dried green tea leaf with an extraction solvent to obtain a green tea extract, and separating the residue to prepare a primary residue;
(2) removing the caffeine component from the green tea extract to prepare a decaffeinated green tea extract;
(3) concentrating the decaffeinated green tea extract to prepare a green tea concentrated extract;
(4) preparing green tea extract powder by pulverizing the green tea concentrated extract; And
(5) A method for manufacturing a green tea tablet, comprising the steps of: (1) preparing a green tea tablet by tableting the green tea extract powder with a tableting excipient comprising a green tea residue prepared according to any one of claims 1 to 3; Gt;
단계 (2)에서 상기 녹차 추출물이 추출용매에 혼합된 상태에서 에틸아세테이트 또는 염화메틸렌을 가하여 카페인이 제거되는 것을 특징으로 하는 녹차 타블렛의 제조방법.6. The method of claim 5,
Wherein the caffeine is removed by adding ethyl acetate or methylene chloride while the green tea extract is mixed with the extraction solvent in step (2).
단계 (4)의 상기 녹차 추출분말은 평균입도가 20 내지 23㎛인 것을 특징으로 하는 녹차 타블렛의 제조방법.6. The method of claim 5,
Wherein the green tea extract powder of step (4) has an average particle size of 20 to 23 占 퐉.
단계 (4)의 상기 분말화는 분무 건조, 감압 증류 및 동결 건조 중에서 선택된 어느 하나의 방법에 따라 수행되는 것을 특징으로 하는 녹차 타블렛의 제조방법.6. The method of claim 5,
Wherein the pulverization of step (4) is performed according to any one of spray drying, vacuum distillation and freeze drying.
단계 (5)에서 타정용 부형제와 상기 녹차 추출분말 3:7 내지 7:3의 중량비로 혼합하여 타정하는 것을 특징으로 하는 녹차 타블렛의 제조방법.6. The method of claim 5,
Wherein in step (5), the tableting excipient and the green tea extract powder are mixed and weighed at a weight ratio of 3: 7 to 7: 3.
단계 (5)의 상기 녹차 타블렛의 카테킨 함량은 30 내지 35wt%인 것을 특징으로 하는 녹차 타블렛의 제조방법.6. The method of claim 5,
Wherein the catechin content of the green tea tablet of step (5) is 30 to 35 wt%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170140075A KR102499774B1 (en) | 2017-10-26 | 2017-10-26 | Method for preparing excipient for tableting comprising green tea residue and method for preparing green tea tablet using the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170140075A KR102499774B1 (en) | 2017-10-26 | 2017-10-26 | Method for preparing excipient for tableting comprising green tea residue and method for preparing green tea tablet using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190046365A true KR20190046365A (en) | 2019-05-07 |
KR102499774B1 KR102499774B1 (en) | 2023-02-15 |
Family
ID=66656109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170140075A Active KR102499774B1 (en) | 2017-10-26 | 2017-10-26 | Method for preparing excipient for tableting comprising green tea residue and method for preparing green tea tablet using the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102499774B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06178650A (en) * | 1992-12-14 | 1994-06-28 | Nikken Food Kk | Preparation of antioxidative instant tea powder |
KR20020028637A (en) * | 2000-10-11 | 2002-04-17 | 박화목 | Process for preparing ginkgo-tea and ginkgo-tea prepared thereby |
KR100673605B1 (en) | 2005-05-27 | 2007-01-24 | 주식회사 이지바이오시스템 | Green tea extract with inhibitory ability of urease activity of Helicobacter pylori and health functional food using same |
KR20140092641A (en) * | 2013-01-16 | 2014-07-24 | 김성호 | The manufacturing method of soluble tablet tea |
KR101630853B1 (en) | 2015-04-23 | 2016-06-16 | 다당앤(주) | Extracts of green tea shielding bitterness using purification process of non-inclusion complex and preparation method of the same |
-
2017
- 2017-10-26 KR KR1020170140075A patent/KR102499774B1/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06178650A (en) * | 1992-12-14 | 1994-06-28 | Nikken Food Kk | Preparation of antioxidative instant tea powder |
KR20020028637A (en) * | 2000-10-11 | 2002-04-17 | 박화목 | Process for preparing ginkgo-tea and ginkgo-tea prepared thereby |
KR100673605B1 (en) | 2005-05-27 | 2007-01-24 | 주식회사 이지바이오시스템 | Green tea extract with inhibitory ability of urease activity of Helicobacter pylori and health functional food using same |
KR20140092641A (en) * | 2013-01-16 | 2014-07-24 | 김성호 | The manufacturing method of soluble tablet tea |
KR101630853B1 (en) | 2015-04-23 | 2016-06-16 | 다당앤(주) | Extracts of green tea shielding bitterness using purification process of non-inclusion complex and preparation method of the same |
Also Published As
Publication number | Publication date |
---|---|
KR102499774B1 (en) | 2023-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080113044A1 (en) | Extracts and Methods Comprising Green Tea Species | |
US7763291B2 (en) | Tea polyphenol composition and method for producing the same | |
KR102211814B1 (en) | Novel extracts of Cynara scolymus, Coffea spp. and Olea europaea for the treatment of metabolic syndrome | |
CN106943768A (en) | Tea Polyphenols and its extracting method and application | |
US20090186125A1 (en) | Process for purifying compounds from tea | |
WO2011080721A2 (en) | A herbal composition as hepatoprotective and treatment for liver disorders | |
GB2466525A (en) | Morus australis Poir antitussive composition and method of preparation thereof | |
KR20200055407A (en) | Preparation method of black Platycodon grandiflorus having increased crude saponin and reduced Platycodin D, inhibiting production of benzopyrene | |
US20110003017A1 (en) | Method for Preparation of Extract from Angelica Gigas Nakai and Composition Containing the Extract | |
CN104982597B (en) | A kind of multi-functional composite instant tea and its preparation method and application | |
KR100872588B1 (en) | A composition containing leather extract having antioxidant effect as an active ingredient | |
WO2015158895A1 (en) | Coffee extracts and formulations containing them | |
KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
CN104095889A (en) | Preparation method of ginko biloba extract | |
KR20190046365A (en) | Method for preparing excipient for tableting comprising green tea residue and method for preparing green tea tablet using the same | |
KR20190052865A (en) | Method for manufacturing fermented green tea extract, and fermented green tea extract therefrom | |
JPS6230711A (en) | Drug for alleviating hypercholesterolemia | |
JP2860494B2 (en) | Aging control instant powdered tea and its manufacturing method | |
US20100166890A1 (en) | Antitussive composition and method for making the same | |
CN113292717B (en) | Tyrosinase inhibitor based on hop extraction and extraction method and application thereof | |
US10034909B2 (en) | Antiobesity agent containing walnut extract | |
KR100592796B1 (en) | Hyperlipidemia prevention and treatment containing green tea catechin as an active ingredient | |
CN114711313B (en) | A tea extract composition and its preparation method and application | |
US20230134529A1 (en) | Labisia pumila extract composition and its pharmaceutical formulation | |
KR101142838B1 (en) | Composition comprising Cyperus rotundus for preventing or treating of neurodegenerative disease and menopausal brain disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20171026 |
|
PG1501 | Laying open of application | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20201021 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20171026 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220722 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230125 |
|
PG1601 | Publication of registration |